The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The role of NECTIN4 in shaping the tumor microenvironment and potentiating the efficacy of immunotherapy in bladder cancer.
 
Kazuki Nishimura
No Relationships to Disclose
 
Ryoichi Maenosono
No Relationships to Disclose
 
Kensuke Hirosuna
No Relationships to Disclose
 
Takuya Tsujino
No Relationships to Disclose
 
Mitsuaki Ishida
No Relationships to Disclose
 
Zyunko Zenko
No Relationships to Disclose
 
Haruhito Azuma
No Relationships to Disclose
 
Kazumasa Komura
Honoraria - Astellas Amgen BioPharama; AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Janssen; Merck Sharp & Dohme; Ono Pharmaceutical; Takeda
 
Akihide Yoshimi
Honoraria - Amgen; Chordia Therapeutics; Daiichi Sankyo; Kyowa Kirin; Life Technologies; MSD; Otsuka; Oxford Nanopore Technologies; Sanofi; Sumitomo Dainippon Pharma
Consulting or Advisory Role - xFOREST Therapeutics
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; xFOREST Therapeutics
Patents, Royalties, Other Intellectual Property - I am an inventor on multiple Japanese patent applications related to nucleic acid–based cancer therapeutics and drug delivery systems, filed in 2025 by the National Cancer Center Japan and collaborating institutions.